SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001640334-18-000561
Filing Date
2018-03-30
Accepted
2018-03-30 10:42:44
Documents
111
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 20-F nymox_20f.htm 20-F 897231
2 CERTIFICATION nymox_ex12b.htm EX-12.A 7672
3 CERTIFICATION nymox_ex12a.htm EX-12.B 7573
4 CERTIFICATION nymox_ex13a.htm EX-13.A 2197
5 CERTIFICATION nymox_ex13b.htm EX-13.B 2170
  Complete submission text file 0001640334-18-000561.txt   5452743

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nymx-20171231.xml EX-101.INS 1261984
7 XBRL TAXONOMY EXTENSION SCHEMA nymx-20171231.xsd EX-101.SCH 96222
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20171231_cal.xml EX-101.CAL 51091
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20171231_def.xml EX-101.DEF 184922
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20171231_lab.xml EX-101.LAB 355351
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20171231_pre.xml EX-101.PRE 309873
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 18725175
SIC: 2835 In Vitro & In Vivo Diagnostic Substances